Fundz

Safi Biotherapeutics raised $5M in seed funding led by J2 Ventures to accelerate clinical production and regulatory path for manufactured red blood cells.

PRIVATESep 12, 2024

Amount Raised

$5 Million

Round Type

Seed

CambridgeManufacturingBiotechnologyHealth Care

Investors

J2 Ventures

Description

Safi Biotherapeutics, based in Cambridge, MA, has raised $5M in seed funding to support its development of manufactured red blood cells as an alternative to donor blood transfusions. This funding will help the company advance its clinical trials and regulatory submissions.

Quick answer

Safi Biotherapeutics raised $5 Million in a Seed round, dated September 12, 2024. Investors: J2 Ventures. Safi Biotherapeutics is based in Cambridge, Massachusetts, United States.

How much did Safi Biotherapeutics raise?
Safi Biotherapeutics raised $5 Million in a Seed round on September 12, 2024.
Who invested in Safi Biotherapeutics?
J2 Ventures is named as investors in this round.
What does Safi Biotherapeutics do?
Safi Biotherapeutics is a developer of manufactured red blood cells (mRBCs) designed to serve as an alternative to donor blood transfusions.
Where is Safi Biotherapeutics based and how big is it?
Safi Biotherapeutics is based in Cambridge, Massachusetts, United States. Fundz records about 11 employees.
Who are the decision-makers at Safi Biotherapeutics?
Fundz holds 2 contacts at Safi Biotherapeutics. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at Safi Biotherapeutics, and when

A new round usually means Safi Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Safi Biotherapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Safi Biotherapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Safi Biotherapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Safi Biotherapeutics

Location

Cambridge, Massachusetts, United States

About

Safi Biotherapeutics is a developer of manufactured red blood cells (mRBCs) designed to serve as an alternative to donor blood transfusions. The company is focused on advancing bio-manufactured red blood cells with targeted immuno-phenotypes for various chronic transfusion indications. Launched in 2020, Safi is progressing the technology to demonstrate the feasibility of an allogeneic, stem-cell sourced mRBC product.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Safi Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Predictive Intelligence
Strategic

ML-powered predictions for Safi Biotherapeutics's next move

See what Strategic adds

Safi Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.